BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) founder and chief medical officer Dr David Berd joined Proactive's Stephen Gunnion with news that the company has started its planed in vivo animal toxicology study of CoviDTH.
Berd telling Proactive that the study will run parallel to the company's preparation of an Investigational New Drug (IND) submission to the US Food and Drug Administration.